Pharmacy | Home | MIMS Malaysia

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

Daratumumab improves PFS in elderly patients with multiple myeloma

Roshini Claire Anthony, 3 hours ago

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) led to improved progression-free survival (PFS) over VMP alone in elderly patients newly diagnosed with multiple myeloma (MM), reflecting the results of the overall ALCYONE* study population.

Denosumab efficacy in GIOP not modified by prior antiosteoporotic therapy

Jairia Dela Cruz, 9 hours ago

Denosumab yields increases in bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis (GIOP), and this benefit is not influenced by prior antiosteoporotic treatment, as shown in a study.

Etanercept does not increase incident uveitis in juvenile idiopathic arthritis

Jairia Dela Cruz, 2 days ago

Among children with juvenile idiopathic arthritis, the risk of developing uveitis is not greater in those treated with etanercept than in those receiving methotrexate, according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.

Long-term data strengthen obinutuzumab as frontline CLL therapy

Pearl Toh, 2 days ago

A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.

Lenabasum shows promise for diffuse cutaneous systemic sclerosis

Roshini Claire Anthony, 3 days ago

The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.

Excerpts from Journey to Pain-Free Living Starts with You – CPD workshop for pharmacists

01 Mar 2018

Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

27 Dec 2017

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Cochrane review confirms Atopiclair efficacy in eczema

22 Dec 2017

Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]

Etanercept does not increase incident uveitis in juvenile idiopathic arthritis

Jairia Dela Cruz, 23 Jun 2018

Long-term data strengthen obinutuzumab as frontline CLL therapy

Pearl Toh, 22 Jun 2018

Lenabasum shows promise for diffuse cutaneous systemic sclerosis

Roshini Claire Anthony, 22 Jun 2018

SPIRIT trials: Ixekizumab proven safe in patients with psoriatic arthritis

Stephen Padilla, 22 Jun 2018

Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2 and -P3) reveals that ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study presented at the Annual European Congress of Rheumatology by the European League Against Rheumatism (EULAR 2018).

Diacerein superior to glucosamine plus chondroitin for mild knee osteoarthritis

Tristan Manalac, 22 Jun 2018

Diacerein appears to be more effective than glucosamine plus chondroitin for patients with mild-to-moderate knee osteoarthritis , according to a study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018).

PET-driven strategy effective, reduces treatment toxicity in advanced Hodgkin lymphoma

Roshini Claire Anthony, 21 Jun 2018

Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.

Eltrombopag proven effective in chronic, persistent immune thrombocytopaenia

Stephen Padilla, 21 Jun 2018

Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!